The IPO Buzz: Attovia Therapeutics (ATTO Proposed) Upsizes IPO to $289 Million
It’s a supersized Tuesday: Attovia Therapeutics (ATTO Proposed), a Phase 1 biotech developing drugs to treat chronic pruritis (itching) and IBD, upsized its IPO to $289 million – up from $200 million – in an S-1/A filing early today (Tuesday, Aug. 4, 2026). The California biotech increased the number of shares to 17 million – up […]
August 4, 2026 Read More